Answers are grounded in this paper and cite their sources.
To our knowledge, this report is the first of an ATR inhibitor as monotherapy and combined with carboplatin. M6620 was well tolerated, with target engagement and preliminary antitumor responses observed.
No takes yet. Share an insight, caveat, or question.
Yap et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: